Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA)

Haidar et al., NCT05648110, SUPERNOVA, NCT05648110, Jun 2026
ProphylaxisDouble-blind RCT · NCT05648110 · 1,663 patients · multinational
Tixagevimab/c.. for COVID-19
SUPERNOVA Haidar et al. NCT05648110 · June 2026
Outcome
Improvement
Relative Risk · 95% CI
Mortality
-104%2.04 · 0.84–4.95
00.511.52+
← Tixagevimab/
cilgavimab
reduces riskIncreased risk →
Higher mortality with treatment
Not statistically significant · p = 0.12

Tixagevimab/cilgavimab for COVID-19

42nd treatment shown to reduce risk in May 2022, now with p = 0.026 from 20 studies, recognized in 33 countries. Efficacy is variant dependent.
Lower risk for hospitalization and cases.

No treatment is 100% effective.
Protocols combine treatments.

6,700+ studies · 220+ treatments

c19early.org
Meta-analysis
RCT 1,663 immunocompromised patients showing higher mortality with tixagevimab/cilgavimab, without statistical significance. Tixagevimab/cilgavimab may have lost efficacy with variants at the time but retain side effects.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.11, BA.5, BA.2.75, XBB2,3, XBB.1.53, ХВВ.1.9.13, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.14.
Important missing comments or errors? Let us know.
Study covers AZD5156 and tixagevimab/cilgavimab.
risk of death, 103.6% higher, RR 2.04, p = 0.12, treatment 24 of 1,102 (2.2%), control 6 of 561 (1.1%), all-cause mortality, day 451, registry.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Haidar et al., 18 Jun 2026, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, preprint, 1 author, trial NCT05648110 (history) (SUPERNOVA). Contact: taylor.cohen@astrazeneca.com.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0